与传统抗凝固药物相比,低剂量全身组织类型等离子素激活剂用于中高风险肺栓塞治疗
Alan De la Rosa1, Adrian Rojas Murguia1, Michael J Brockman1
1Division of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Cardiovascular & hematological disorders drug targets
|January 31, 2025
概括
低剂量组织型等离子体激活剂 (tPA) 与单独抗凝药相比,在中高风险肺栓塞 (PE) 患者中改善了右心室功能. 这种治疗也导致出血事件减少,住院时间缩短.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 紧急医疗 紧急医疗
背景情况:
- 肺栓塞 (PE) 是导致死亡的主要原因.
- 目前对中高风险PE的治疗方法包括抗凝血 (AC) 或血栓解血疗法.
- 存在有限的数据,比较低剂量的组织类型等离子体激活剂 (tPA) 与PE的AC.
研究的目的:
- 为了追溯比较低剂量tPA与单独AC的疗效和安全性.
- 评估对右心室 (RV) 功能,住院死亡率和出血并发症的影响.
- 评估中等至高风险PE患者的结果.
主要方法:
- 单中心,回顾性队列试验. 一个中心,回顾性队列试验.
- 分析了88名中等至高风险PE患者.
- 主要终点包括VR功能变化,住院死亡率和严重出血.
主要成果:
- 低剂量tPA (n=26) 在24小时内显著改善了VR功能;AC组 (n=62) 没有.
- tPA组的出血事件较少,停留时间较短 (LOS).
- 没有观察到基线生命体征或PESI分数的显著差异.
结论:
- 低剂量,长时间输液tPA可能对中等风险PE有效和安全.
- 与AC相比,低剂量的tPA改善了肺动脉缩压 (PASP) 并恢复了RV功能.
- 这表明tPA在精选的PE患者中是AC的可行替代品.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
601
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
146
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
146
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
461
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
461
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131


